Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis.
Authors:Hussein N Yassine|||Qingru Feng|||Ida Azizkhanian|||Varun Rawat|||Katherine Castor|||Alfred N Fonteh|||Michael G Harrington|||Ling Zheng|||Bruce R Reed|||Charles DeCarli|||William J Jagust|||Helena C Chui
Journal: JAMA neurology
Publication Type: Journal Article
Date: 2016
DOI: 10.1001/jamaneurol.2016.1924
ID: 27532692
Affiliations:
Affiliations
Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.|||Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.|||Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.|||Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.|||Huntington Medical Research Institute, Pasadena, California.|||Huntington Medical Research Institute, Pasadena, California.|||Huntington Medical Research Institute, Pasadena, California.|||Department of Neurology, University of Southern California, Los Angeles.|||Department of Neurology, University of California Davis, Sacarmento.|||Department of Neurology, University of California Davis, Sacarmento.|||Helen Wills Neuroscience Institute, University of California Berkeley.|||Department of Neurology, University of Southern California, Los Angeles.
Abstract
Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain.
